Dotarem

Dotarem

Stability Down to its Molecular Core

Dotarem® (gadoterate meglumine) with its unique profile, provides the highest molecular stability, minimizing the risk of gadolinium release. The first macrocyclic & ionic GBCA molecule sold in the US. Patented manufacturing process. More than 100 million global doses administered with zero unconfounded cases of NSF.

[Available in Northern Ireland and Republic Of Ireland]

Features

  • Very high safety profile
  • Very high stability profile
  • Available in 10mls and 20mls
  • Optimal diagnostic performance

Benefits

  • No confirmed cases of unconfounded NSF
  • Low rate of adverse drug reactions
  • No dissociated Dotarem
  • No visible brain hyperintensities
  • Flexible
  • Clinician confidence

20191122 UNIK Brochure (PDF)

Download

Dotarem Brochure Clincial (PDF)

Download